Safety and Efficacy of Low-dose Prostacyclin Administration and Blood Pressure Target in Addition to Standard Therapy, as Compared to Standard Therapy Alone, in Post-cardiac-arrest-syndrome Patients - a Randomized, Controlled, Double-blinded Investigator-initiated Trial. (ENDO-RCA)

NCT02685618 Phase 2 COMPLETED

Objective: Safety and efficacy of low-dose prostacyclin administration and blood pressure target in addition to standard therapy, as compared to standard therapy alone, in post-cardiac-arrest-syndrome (PCAS) patients.

Details

Lead sponsor	Pär Johansson
Phase	Phase 2
Status	COMPLETED
Enrolment	50
Start date	2016-02
Completion	2017-02-27

Conditions

• Cardiac Arrest

Interventions

• Iloprost
• Saline
• Phillips M1006B, offset by -10mmHg
• Philips M1006B, No offset

Primary outcomes

• Mean change i plasma biomarkers reflecting endothelial activation and damage — 48 hours
  Mean change in biomarkers indicative of endothelial activation and damage (sE-selectin, syndecan-1, soluble thrombomodulin (sTM), soluble vascular endothelial growth factor (sVEGF), nucleosomes) and sympathoadrenal overactivation (epinephrine/norepinephrine) from baseline to 48 hours post-randomization.

Countries

Denmark